The recent proposal by the Biden administration to appropriate drug patents when their prices are adjudged excessive has raised serious concerns within the pharmaceutical industry and wider legal community. This move, intended as a response to the high cost of medications, is likely to generate considerable legal opposition.
Legal experts have warned about the potential unintended repercussions of this measure on the pharmaceutical industry. Their concerns are rooted not only in the legal complexities of enforcing such a policy, but also in its potential to stifle innovation by disincentivising the development of new drugs.
The implications of the proposed changes are far-reaching, and may not align with the administration’s initial intentions. Read more on the complexities around this issue and expert opinions in Kelly Lienhard’s article on Law360.